2,497 publications from this institution
Maintaining low supply impedance is a critical task in modern high-performance chip and system design, and this depends on how the current flows on the chip, package, and board power distribution layers. Using a simple inductive pickup loop previously described, we measure the per-pin via currents for a large VLSI chip in operation. Interestingly, the variation in AC current across the package was only 33%, indicating that for this chip current crowding was not an issue. Furthermore, we measured the board bypass capacitance currents as well, and found that the capacitors supplied between 80% and 120% of the peak transient currents of the pins to which they were connected. Since the maximum current is only slightly larger than the current required by the attached pin, the board bypass capacitance primarily affects the pin it is connected to, and does not really bypass the other VDD pins in that region.
The meta-analysis by Mauri et al. ( 1 ) from nine neoadjuvant trials is important given the confl icting evidence from published studies.However, we would like to make two points that arise from this analysis.First, to establish the benefi t of neoadjuvant therapy over adjuvant therapy, treatment regimens in the two arms should be identical in terms of drugs used and in terms of scheduling.Mauri et al. acknowledge that postoperative chemotherapy was administered to patients randomly assigned to the neoadjuvant arm in approximately half of studies ( 2 -5 ) , representing approximately a quarter of the dataset pooled (986 patients).This sizeable proportion may have biased results in favor of adjuvant therapy.Ideally, these studies should have been excluded from pooling, but this exclusion would have resulted in pooled data available on only 2960 patients, of which a few more than half (1523 patients) would have been from a single study ].Data from sensitivity analysis with and without the four studies ( 2 -5 ) in which patients received both adjuvant and neoadjuvant chemotherapy should be obtained to assess their potential impact on the primary outcomes assessed and the robustness of the authors' conclusions.Second, Mauri et al. focused on the inability of neoadjuvant chemotherapy to improve any of the primary outcomes assessed, compared with adjuvant therapy, but this analysis should be recognized as a success.Data presented show the clear superiority of neoadjuvant therapy in breastconserving surgery, an important issue for many patients.Furthermore, the ability to obtain tumor tissue by core biopsy before and during neoadjuvant therapy, in addition to the surgical specimen itself, offers a major opportunity for translational research.